

Walker Chandiook & Co LLP

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/PoD1/P/CIR/2024/54 dated 22 May 2024 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Madhu Sudan

Madhu Sudan Malpani

Partner

Membership No. 517440



UDIN: 25517440BMLKFO6325

Place: Gurugram

Date: 31 July 2025

Jubilant Ingrevia Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437

Statement of Standalone Unaudited Financial Results for the Quarter Ended 30 June 2025

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2025	2025	2024	2025
1	Revenue from operations				
	a) Sales/Income from operations	96455	95240	95528	388095
	b) Other operating income	853	1958	1381	6028
	Total revenue from operations	97308	97198	96909	394123
2	Other income	1110	3560	922	8101
3	Total income (1+2)	98418	100758	97831	402224
4	Expenses				
	a) Cost of materials consumed	47549	49637	53032	205975
	b) Purchases of stock-in-trade	3240	3206	740	5668
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	2412	(1052)	(121)	(2851)
	d) Employee benefits expense	9661	8625	9222	37607
	e) Finance costs	1483	1574	1669	6507
	f) Depreciation and amortisation expense	3823	3679	3633	14732
	g) Other expenses:				
	- Power and fuel expense	10390	10645	12033	47772
	- Others	11918	13349	13189	52478
	Total expenses	90476	89663	93397	367888
5	Profit before tax (3-4)	7942	11095	4434	34336
6	Tax expense				
	- Current tax	1667	2246	955	7271
	- Deferred tax	374	(138)	202	723
7	Net profit for the period/year (5-6)	5901	8987	3277	26342
8	Other comprehensive income (OCI)				
	i) a) Items that will not be reclassified to profit or loss	(70)	206	(35)	(281)
	b) Income tax relating to items that will not be reclassified to profit or loss	18	(21)	9	71
	ii) a) Items that will be reclassified to profit or loss	-	-	-	-
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
9	Total comprehensive income for the period/year (7+8)	5849	9172	3251	26132
10	Earnings per share of ₹ 1 each (not annualised for the quarters)				
	Basic (₹)	3.70	5.64	2.06	16.54
	Diluted (₹)	3.70	5.64	2.06	16.54
11	Paid-up equity share capital (face value per share ₹ 1)	1593	1593	1593	1593
12	Reserves excluding revaluation reserves (other equity)				242495
	See accompanying notes to the Standalone Unaudited Financial Results				



**SIGNED FOR
IDENTIFICATION
PURPOSES**



Jubilant Ingrevia Limited

Note 1: Standalone Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter Ended 30 June 2025

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2025	2025	2024	2025
1	Segment revenue				
	a. Speciality Chemicals	51063	52260	45287	200799
	b. Nutrition & Health Solutions	16401	17256	17250	71240
	c. Chemical Intermediates	35798	34555	39133	147384
	Total	103262	104071	101670	419423
	Less : Inter segment revenue	5954	6873	4761	25300
	Total revenue from operations	97308	97198	96909	394123
	a. Speciality Chemicals	45197	45712	40820	176498
	b. Nutrition & Health Solutions	16383	17247	17227	71177
	c. Chemical Intermediates	35728	34239	38862	146448
	Total	97308	97198	96909	394123
2	Segment results (profit before tax and interest)				
	a. Speciality Chemicals	10742	12292	5897	35589
	b. Nutrition & Health Solutions	357	1701	1568	8052
	c. Chemical Intermediates	189	132	1166	5007
	Total	11288	14125	8631	48648
	Less: i. Interest (finance costs)	1483	1574	1669	6507
	ii. Un-allocable expenditure (net of un-allocable income)	1863	1456	2528	7805
	Profit before tax	7942	11095	4434	34336
3	Segment assets				
	a. Speciality Chemicals	241328	243167	237609	243167
	b. Nutrition & Health Solutions	57638	54410	38705	54410
	c. Chemical Intermediates	129536	115324	125791	115324
	d. Unallocable corporate assets	44977	39171	33919	39171
	Total segment assets	473479	452072	436024	452072
4	Segment liabilities				
	a. Speciality Chemicals	47529	52919	40241	52919
	b. Nutrition & Health Solutions	13197	12379	12590	12379
	c. Chemical Intermediates	52626	38614	48682	38614
	d. Unallocable corporate liabilities	109915	104072	106276	104072
	Total segment liabilities	223267	207984	207789	207984



**SIGNED FOR
IDENTIFICATION
PURPOSES**




Jubilant Ingrevia Limited

Note 2: Additional disclosure as per Regulation 52 (4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Standalone)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June (Unaudited) 2025	31 March (Audited) 2025	30 June (Unaudited) 2024	
1	Debt service coverage ratio (in times)# <i>Definition: EBITDA/(finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts)</i> <i>{EBITDA: Profit before tax + depreciation and amortisation expense + finance costs}</i>	4.05	5.85	5.83	6.21
2	Interest service coverage ratio (in times) <i>Definition: EBITDA/finance costs</i>	8.93	10.39	5.83	8.54
3	Bad debts to account receivable ratio (%)# <i>Definition: Bad debts/average of opening and closing trade receivables</i> <i>{Bad debts: Impairment balance as per statements of profit and loss}</i>	0.02%	0.03%	-0.04%	0.03%
4	Debtors turnover (in times)# <i>Definition: Revenue from operations/average of opening and closing trade receivables</i>	1.62	1.67	1.75	6.94
5	Inventory turnover (in times)# <i>Definition: Cost of goods sold/average of opening and closing inventories</i>	0.63	0.64	0.69	2.64
6	Operating margin (%) <i>Definition: Operating profit/revenue from operations</i> <i>{Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and amortisation expense - other expenses}</i> <i>{Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods, stock-in-trade and work-in-progress}</i>	8.55%	9.37%	5.35%	8.31%
7	Net profit margin (%) <i>Definition: Net profit/total income</i>	5.99%	8.92%	3.35%	6.55%
8	Net worth (In ₹ Lakhs) <i>{Net worth: Equity share capital + other equity}</i>	250212	244088	228235	244088
9	Debt equity ratio (in times) <i>Definition: Net debts/net worth</i> <i>{Net debts: Long term borrowings (gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank balances}</i>	0.30	0.30	0.36	0.30
10	Current ratio (in times) <i>Definition: Current assets/current liabilities</i>	1.16	1.17	1.20	1.17
11	Long term debt to working capital (in times) <i>Definition: Long term debt/working capital</i> <i>{Long term debt: Long term borrowings (gross of transaction costs)}</i> <i>{working capital: Current assets - current liabilities}</i>	1.66	1.77	2.07	1.77
12	Current liability ratio (in times) <i>Definition: Current liabilities/total liabilities</i>	0.71	0.68	0.61	0.68
13	Total debts to total assets (in times) <i>Definition: Total debts/total assets</i> <i>{Total debts: Long term borrowings (gross of transaction costs) + short term borrowings}</i>	0.17	0.17	0.19	0.17



[Handwritten Signature]



SIGNED FOR IDENTIFICATION PURPOSES

not annualised for the quarters

Notes to standalone unaudited financial results (cont'd):

3. These standalone unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
4. During the quarter, the Company has made third tranche of its investment in O2 Renewable Energy XVIII Private Limited, a group company of O2 Power SG PTE. LTD, Singapore, a leading renewable energy developer towards establishing renewable energy power generation through solar and wind sources. It aims to access renewable energy through a captive arrangement, fulfilling the Company's power requirements and meeting its increasing demand through green energy. Post the third tranche of investment, O2 Renewable Energy XVIII Private Limited has become an associate of the Company.
5. As on 30 June 2025, the Company has outstanding unsecured listed commercial papers (CPs) of ₹ 15000 lakhs. These CPs are listed on the National Stock Exchange of India. Details of CPs are as follows:

ISIN No.	Issue date	Due date of repayment	Redemption amount
INE0BY014375	23 May 2025	22 July 2025	₹ 5000 lakhs
INE0BY014383	06 June 2025	31 July 2025	₹ 10000 lakhs

6. The figures for the quarter ended 31 March 2025, as reported in the standalone financial results, are the balancing figures between the audited figures for the year ended 31 March 2025 and the published year to date figures for 31 December 2024, which were subjected to limited review by the statutory auditors.
7. Previous periods figures have been regrouped/reclassified, wherever necessary. The impact of such reclassification/regrouping is not material to the financial results.
8. The above standalone unaudited financial results were reviewed by the Audit Committee on 30 July 2025 and approved by the Board of Directors at its meeting held on 31 July 2025. These results have been subjected to limited review by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on standalone financial results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.


For Jubilant Ingrevia Limited



Deepak Jain
CEO & Managing Director

Place : Noida

Date : 31 July 2025



**SIGNED FOR
IDENTIFICATION
PURPOSES**



Notes to consolidated unaudited financial results (cont'd):

3. These consolidated unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
4. During the quarter, the Holding Company has made third tranche of its investment in O2 Renewable Energy XVIII Private Limited, a group company of O2 Power SG PTE. LTD, Singapore, a leading renewable energy developer towards establishing renewable energy power generation through solar and wind sources. It aims to access renewable energy through a captive arrangement, fulfilling the Holding Company's power requirements and meeting its increasing demand through green energy. Post the third tranche of investment, O2 Renewable Energy XVIII Private Limited has become an associate of the Holding Company.
5. As on 30 June 2025, the Holding Company has outstanding unsecured listed commercial papers (CPs) of ₹ 15000 lakhs. These CPs are listed on the National Stock Exchange of India. Details of CPs are as follows:


ISIN No.	Issue date	Due date of repayment	Redemption amount
INEOBY014375	23 May 2025	22 July 2025	₹ 5000 lakhs
INEOBY014383	06 June 2025	31 July 2025	₹ 10000 lakhs

6. The figures for the quarter ended 31 March 2025, as reported in the consolidated financial results, are the balancing figures between the audited figures for the year ended 31 March 2025 and the published year to date figures for 31 December 2024, which were subjected to limited review by the statutory auditors.
7. Previous periods figures have been regrouped/reclassified, wherever necessary. The impact of such reclassification/regrouping is not material to the financial results.
8. The above consolidated unaudited financial results were reviewed by the Audit Committee on 30 July 2025 and approved by the Board of Directors at its meeting held on 31 July 2025. These results have been subjected to limited review by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on consolidated financial results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Ingrevia Limited


Deepak Jain
CEO & Managing Director

Place : Noida
Date : 31 July 2025



**SIGNED FOR
IDENTIFICATION
PURPOSES**

